What it sells
Makes human microbiology computable.
Business model breakdown
Buyer: who owns the budget?
UnverifiedR&D heads at pharma and food/ingredient companies, via pilot programs.
Trigger: what makes them buy now?
Microbiome is a largely unmodeled variable in how drugs and ingredients behave; need earlier risk flags and sharper go/no-go calls.
Workflow: what inputs become what output?
Capture multi-omics readouts, run drug/food/compound experiments, train models, design next experiments.
Economics: what it saves and how it charges
UnverifiedLab-in-the-loop platform sold through pilots/projects (screening for metabolism, toxicity, efficacy, community shifts); commercial terms not published.
Distribution: how it reaches customers
Pilot-led ('Explore a pilot').
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-03-02 | — | €2.9M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.